Skip to main
EDSA
EDSA logo

EDSA Stock Forecast & Price Target

EDSA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Edesa Biotech Inc. has demonstrated promising results from its Phase 2b trial of EB01, which showed significant improvements in skin health among 200 patients with allergic contact dermatitis, indicating the potential for safer treatment alternatives to traditional options. The company's strategic plans to expand into additional indications and geographic markets, coupled with the potential advancement of other promising candidates like EB05 and EB07, could enhance revenue prospects and drive future growth. Collectively, these factors contribute to a strong positive outlook for Edesa Biotech's stock in the competitive biotechnology landscape.

Bears say

Edesa Biotech Inc is projected to continue experiencing negative cash flows from operating activities through FY2026, indicating ongoing financial strain. The company reported negative operating cash flows in FY2024, which raises concerns about its financial sustainability and ability to fund its product development initiatives. Given these ongoing cash flow challenges, the outlook for Edesa Biotech's financial stability remains bleak.

EDSA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edesa Biotech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edesa Biotech Inc (EDSA) Forecast

Analysts have given EDSA a Strong Buy based on their latest research and market trends.

According to 1 analysts, EDSA has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edesa Biotech Inc (EDSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.